Dyne Therapeutics Financial Results
Dyne Therapeutics reported Q3 2026 financial results, highlighting a cash position of $684.1 million to support operations into late 2026. The company is preparing for a potential Q1 2027 U.S. launch of z-rostudirsen for DMD, which is currently under FDA priority review with a PDUFA date of January 21, 2027.
- Term
- Q3 2026
“As we work toward potential commercialization, we are investing across multiple programs with the goal of unlocking the full value of our FORCE platform. This includes preparations for the potential U.S. launch of z-rostudirsen for exon 51 DMD, if approved, and topline data from the registrational expansion cohort of the ACHIEVE trial for z-basivarsen in DM1, both expected in the first quarter of 2027.”
John Cox, president and chief executive officer of Dyne